Biocryst Pharmaceuticals (BCRX) Cash from Investing Activities (2010 - 2026)

Biocryst Pharmaceuticals' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$268.6 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 1091.5% year-over-year to -$268.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$309.4 million (down 707.55% YoY) and the FY2025 annual result came in at -$13.7 million, down 126.04% from the prior year.
• Cash from Investing Activities was -$268.6 million for Q1 2026 at Biocryst Pharmaceuticals, down from -$83.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $77.2 million in Q4 2022 and bottomed at -$268.6 million in Q1 2026.
• A 5-year average of -$28.8 million and a median of -$2.4 million in 2024 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 2263.37% — and 2025, when it soared 1289.34%.
• Biocryst Pharmaceuticals' Cash from Investing Activities stood at $77.2 million in 2022, then tumbled by 136.87% to -$28.5 million in 2023, then soared by 162.5% to $17.8 million in 2024, then slumped by 569.11% to -$83.5 million in 2025, then tumbled by 221.78% to -$268.6 million in 2026.
• Business Quant data shows BCRX's Cash from Investing Activities at -$268.6 million in Q1 2026, -$83.5 million in Q4 2025, and $13.6 million in Q3 2025.